Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model

Table 1

Baseline characteristics of patients.

Number	Age (y)	Gender	Tumor staging	Pathological types	Lauren classification; HER2 status	Metastasis sites	Previous treatment	MiniPDX models’ chemotherapy regimen and doses.
#1	70	Female	IV	Adenocarcinoma	Intestinal type; HER2 positive	Liver lesions	1st line: sintilimab/trastuzumab/XELOX (8 cycles)	1, Irinotecan: 50 mg/kg, IP, day 1 and day 5;
								2, Nab-paclitaxel: 20 mg/kg, IV, day 1–day 5;
								3, Anlotinib: 3 mg/kg, PO, day 1–day 7;
								4, Apatinib: 100 mg/kg, PO, day 1–day 7;
								5, Pyrotinib: 10 mg/kg, PO, day 1–day 7;
#2	66	Male	IV	Adenocarcinoma	Intestinal type; HER2 positive	Liver lesions	1st line: SOX (4 cycles) + trastuzumab/SOX (3 cycles); maintenance treatment: trastuzumab + S-1	1, Oxaliplatin + capecitabine: (Oxa)5 mg/kg, IP, day 1+ (Cape), 400 mg/kg, PO, day 1–day 7;
								2, Oxaliplatin + CF + 5-FU: (Oxa)5 mg/kg, IP, day 1 + CF, 50 mg/kg, IP, day 1 + 5-FU, 25 mg/kg, IP, day 1–day 5;
								3, Docetaxel + S-1: (Doc)20 mg/kg, IP, day 1 and day 5 + S-1, 10 mg/kg, PO, day 1–day 5;
								4, S-1: S-1, 10 mg/kg, PO, day 1–day 5;
								5, Irinotecan + apatinib: (Iri)50 mg/kg, IP, day 1 and day 5+(Apa) 100 mg/kg, PO, day 1–day 7;
#3	67	Female	IV	Adenocarcinoma	Intestinal type; HER2 positive	Liver lesions	1st line: trastuzumab/XELOX (6 cycles)	1, Irinotecan: 50 mg/kg, IP, day 1 and day 5;
								2, Nab-paclitaxel: 20 mg/kg, IV, day 1–day 5;
								3, Anlotinib: 3 mg/kg, PO, day 1–day 7;
								4, Apatinib: 100 mg/kg, PO, day 1–day 7;
								5, Pyrotinib: 10 mg/kg, PO, day 1–day 7;
#4	34	Female	IV	Signet ring cell carcinoma	Diffuse type; HER2 negative	Pelvic cavity	1st line: camrelizumab/apatinib/SOX (3 cycles);	1, Nab-paclitaxel + S-1: nab-paclitaxel 20 mg/kg, IV, day 1–day 5 + S-1, 10 mg/kg, PO, day 1–day 5;
								2, Docetaxel + S-1: (Doc)20 mg/kg, IP, day 1 and day 5 + S-1, 10 mg/kg, PO, day 1–day 5;
								3, Irinotecan + apatinib: (Iri)50 mg/kg, IP, day 1 and day 5+(Apa)100 mg/kg, PO, day 1–day 7;
								4, Docetaxel + apatinib: (Doc): 20 mg/kg, IP, day 1 and day 5+(Apa)100 mg/kg, PO, day 1-day;
								5, Fruquintinib + nab-paclitaxel: (Fru)20 mg/kg, PO, day 1–day 7+(Pac)20 mg/kg, IV, day 1–day 5

Notes: Tumors were staged according to NCCN guidelines for gastric cancer (2021 V1). Metastasis sites were defined by the location of the main metastatic lesions.